.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,977,113

« Back to Dashboard

Details for Patent: 5,977,113

Title: 4-heteroaryl-1-piperazine alkylamines and their therapeutic utility
Abstract:Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s): Glamkowski; Edward J. (Warren, NJ), Chiang; Yulin (Covent Station, NJ), Strupczewski; Joseph T. (Flemington, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Nemoto; Peter A. (Raritan, NJ), Tegeler; John J. (Bridgewater, NJ)
Assignee: Hoechst Marion Roussel, Inc. (Kansas City, MO)
Filing Date:Jun 06, 1995
Application Number:08/466,241
Claims:1. A compound having the formula: ##STR134## wherein, X is --O--, --S--, ##STR135## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups, wherein aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy or halogen when p is 2 and X is --O--;

in which (R.sub.1) is R.sub.20, R.sub.21 or R.sub.22, wherein:

R.sub.20 is --(CH.sub.2).sub.n --, where n is 2, 3, 4 or 5;

R.sub.21 is

--CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --,

--CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2,

--CH.sub.2 --CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --CH.sub.2 --, or

--CH.sub.2 --CH.sub.2 --C.tbd.C--CH.sub.2 --,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1 -C.sub.6 linear alkyl group, phenyl group or ##STR136## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.12 straight or branched chain) alkyl, ##STR137## and where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl and piperazinyl;

in which aryl is phenyl or ##STR138## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

with the proviso that if either one of R.sub.18 and R.sub.19 is hydrogen and the other is hydrogen or alkyl, then X is not S when Y is hydrogen and (R.sub.1) is R.sub.20 or R.sub.21 ;

with the proviso that when R.sub.18 is alkyl and R.sub.19 is --C(.dbd.O)--(C.sub.1 -C.sub.12) alkyl, or when R.sub.19 is alkyl and R.sub.18 is --C(.dbd.O)--(C.sub.1 -C.sub.12) alkyl, X is not S when Y is hydrogen and (R.sub.1) is R.sub.20 ;

with the proviso that when R.sub.18 and R.sub.19 are both hydrogen, (R.sub.1) is not R.sub.20 or R.sub.21 when X is O and Y is hydrogen;

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

2. A pharmaceutical composition which comprises the compound of claim 1 and a pharmaceutically acceptable carrier therefor.

3. The compound of claim 1, wherein X is --N(R.sub.2)--.

4. The compound of claim 3, wherein R.sub.2 is (C.sub.1 -C.sub.18) alkanoyl.

5. The compound of claim 1, wherein R.sub.18 and R.sub.19 are hydrogen.

6. The compound of claim 1, wherein NR.sub.18 R.sub.19 form a piperidinyl ring.

7. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

8. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of the compound of claim 1.

9. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

10. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1.

11. A compound of the formula: ##STR139## wherein, X is --O--, --S--, --NH--, or ##STR140## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C.sub.3 -C.sub.10)cycloalkyl, aroyl, (C.sub.2 -C.sub.18)alkanoyl, (C.sub.1 -C.sub.18)alkoxycarbonyl, and phenylsulfonyl groups;

aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino;

R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 --, where n is 0, 1, 2 or 3; or

--CHR.sub.24 CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CHR.sub.24 --,

--CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --,

--CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or

--CHR.sub.24 --CR.sub.23 R.sub.24 --C.tbd.C--CHR.sub.24,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.23 is hydrogen, (C.sub.1 -C.sub.18) linear alkyl, phenyl, hydroxy, (C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR141## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined, wherein aryl is as defined hereinafter;

R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR142## where Z.sub.1 and p are as previously defined, wherein aryl is as defined hereinafter;

R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S;

with the proviso that R.sub.23 is not hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR143## when R.sub.27 is hydrogen and R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR144## with the proviso that R.sub.24 is not hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR145## when R.sub.27 is hydrogen and n is 0, or when R.sub.27 is hydrogen and R.sub.23 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR146## or when R.sub.1 is --CHR.sub.24 --CH.dbd.CH--CHR.sub.24 -- or --CHR.sub.24 --C.dbd.C--CHR.sub.24 ;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.18 straight or branched chain)alkyl,

--C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)-pyridyl, ##STR147## where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl;

where the piperidinyl or piperazinyl ring is optionally substituted by ##STR148## where X, Y, and p are as previously defined; where R.sub.4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C.sub.1 -C.sub.6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C.sub.1 -C.sub.18)acyl amino, (C.sub.1 -C.sub.18)alkanoyl, trifluoromethyl, nitro, chlorine, fluorine, bromine, --O--C(.dbd.O)--(C.sub.1 -C.sub.18 straight or branched chain)alkyl or --C(.dbd.O)-aryl;

R.sub.28 is hydrogen, (C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.6)alkyl, or aryl;

m is 1, 2, or 3;

aryl is phenyl or ##STR149## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

with the proviso that if R.sub.18 is hydrogen and R.sub.19 is --C(.dbd.O)-pyridyl, or if R.sub.19 is hydrogen and R.sub.18 is --C(.dbd.O)-pyridyl, then when X is --NR.sub.2 --, R.sub.2 is not lower alkyl unless Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, or iodine, and when X is O, S, or --NH--, then Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, or iodine;

and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group, in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group;

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

12. The compound of claim 11, wherein X is --N(R.sub.2)--.

13. The compound of claim 12, wherein R.sub.2 is (C.sub.2 -C.sub.18) alkanoyl or (C.sub.1 -C.sub.18)alkoxycarbonyl.

14. The compound of claim 11, wherein R.sub.18 and R.sub.19 are hydrogen.

15. The compound of claim 11, wherein R.sub.18 is hydrogen and R.sub.19 is --(C.dbd.O)pyridyl.

16. The compound of claim 11, wherein R.sub.18 is hydrogen and R.sub.19 is ##STR150##

17. The compound of claim 11, wherein NR.sub.18 R.sub.19 form a piperidinyl ring.

18. An antipsychotic composition, which comprises the compound of claim 11 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

19. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 11.

20. An analgesic composition, which comprises the compound of claim 11 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.

21. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 11.

22. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 11, wherein the compound contains an acylated hydroxy group, or an acylated amino group.

23. The depot pharmaceutical composition of claim 22, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group.

24. The composition of claim 22, which contains a pharmaceutically acceptable oil.

25. The composition of claim 24, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

26. The composition of claim 23, which contains a pharmaceutically acceptable oil.

27. The composition of claim 26, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

28. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 22 sufficient to produce a long acting antipsychotic effect.

29. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 23 sufficient to produce a long acting antipsychotic effect.

30. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 27 sufficient to produce a long acting antipsychotic effect.

31. A compound of the formula: wherein,

X is --O--, --S--, --NH--, or --N(R.sub.2)--;

R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups;

aryl is as defined hereinafter;

p is 2;

Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino when X is --S--, --NH--, or --N(R.sub.2)--;

Y is lower alkyl, trifluoromethyl, nitro, or amino when X is --O--;

R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 --, where n is 0, 1, 2 or 3; or

--CHR.sub.24 CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CHR.sub.24 --,

--CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --,

--CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or

--CHR.sub.24 --CR.sub.23 R.sub.24 --C.tbd.C--CHR.sub.24,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.23 is hydrogen, (C.sub.1 -C.sub.18) linear alkyl, phenyl, hydroxy, (C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR151## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined, wherein aryl is as defined hereinafter;

R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkoxy(C.sub.1-C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR152## where Z.sub.1 and p are as previously defined, wherein aryl is as defined hereinafter;

R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.18 straight or branched chain)alkyl,

--C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)-pyridyl, ##STR153## where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl;

where the piperidinyl or piperazinyl ring is optionally substituted by ##STR154## where X, Y, and p are as previously defined; where R.sub.4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C.sub.1 -C.sub.6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C.sub.1 -C.sub.18)acyl amino, (C.sub.1 -C.sub.18)alkanoyl, trifluoromethyl, nitro, chlorine, fluorine, bromine, --O--C(.dbd.O)--(C.sub.1 -C.sub.18 straight or branched chain)alkyl or --C(.dbd.O)-aryl;

R.sub.28 is hydrogen, (C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.6)alkyl, or aryl;

m is 1, 2, or 3;

aryl is phenyl or ##STR155## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

with the proviso that if R.sub.18 is hydrogen and R.sub.19 is --C(.dbd.O)-pyridyl, or if R.sub.19 is hydrogen and R.sub.18 is --C(.dbd.O)-pyridyl, then when X is --NR.sub.2 --, R.sub.2 is not lower alkyl unless Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, or iodine, and when X is O, S, or --NH--, then Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, or iodine;

and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group, in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group;

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

32. The compound of claim 31, wherein X is --N(R.sub.2)--.

33. The compound of claim 32, wherein R.sub.2 is (C.sub.1 -C.sub.18)alkanoyl or (C.sub.1 -C.sub.18)alkoxycarbonyl.

34. The compound of claim 31, wherein R.sub.18 and R.sub.19 are hydrogen.

35. The compound of claim 31, wherein R.sub.18 is hydrogen and R.sub.19 is --(C.dbd.O)pyridyl.

36. The compound of claim 31, wherein R.sub.18 is hydrogen and R.sub.19 is ##STR156##

37. The compound of claim 31, wherein NR.sub.18 R.sub.19 form a piperidinyl ring.

38. An antipsychotic composition, which comprises the compound of claim 31 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

39. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 31.

40. An analgesic composition, which comprises the compound of claim 31 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.

41. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 31.

42. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 31, wherein the compound contains an acylated hydroxy group, or an acylated amino group.

43. The depot pharmaceutical composition of claim 42, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group.

44. The composition of claim 42, which contains a pharmaceutically acceptable oil.

45. The composition of claim 44, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

46. The composition of claim 43, which contains a pharmaceutically acceptable oil.

47. The composition of claim 46, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

48. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 42 sufficient to produce a long acting antipsychotic effect.

49. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 43 sufficient to produce a long acting antipsychotic effect.

50. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 47 sufficient to produce a long acting antipsychotic effect.

51. A compound of the formula: wherein,

X is --O--, --S--, --NH--, or --N(R.sub.2)--;

R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C.sub.3 -C.sub.10)cycloalkyl, aroyl, (C.sub.2 -C.sub.18)alkanoyl, (C.sub.1 -C.sub.18)alkoxycarbonyl, and phenylsulfonyl groups;

aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino;

R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 --, where n is 0, 1, 2 or 3; or

--CHR.sub.24 CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CHR.sub.24 --,

--CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --,

--CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --,

--CHR.sub.24 --C.tbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or

--CHR.sub.24 --CR.sub.23 R.sub.24 --C.tbd.C--CHR.sub.24 --,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.23 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy, (C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR157## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined, wherein aryl is as defined hereinafter;

R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR158## where Z.sub.1 and p are as previously defined, wherein aryl is as defined hereinafter;

R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.18 straight or branched chain)alkyl,

--C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl,

--C(.dbd.O)-pyridyl, ##STR159## ; and where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl and piperazinyl, where the piperidinyl or piperazinyl ring is substituted by ##STR160## where X, Y, and p are as previously defined; where R.sub.4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C.sub.1 -C.sub.6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C.sub.1 -C.sub.18)acyl amino, (C.sub.1 -C.sub.18)alkanoyl, trifluoromethyl, nitro, chlorine, fluorine, bromine, --O--C(.dbd.O)--(C.sub.1 -C.sub.18 straight or branched chain)alkyl or --C(.dbd.O)-aryl;

where R.sub.28 is hydrogen (C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.6)alkyl or aryl;

where m is 1, 2, or 3;

with the proviso that if R.sub.18 is hydrogen, (C.sub.1 -C.sub.18 straight or branched chain)alkyl, --C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl, or --C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl, then R.sub.19 is selected from the group consisting of --C(.dbd.O)-pyridyl and ##STR161## with the proviso that if R.sub.19 is hydrogen, (C.sub.1 -C.sub.18 straight or branched chain)alkyl, --C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl, or --C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl, then R.sub.18 is selected from the group consisting of --C(.dbd.O)-pyridyl and ##STR162## with the proviso that if R.sub.18 is hydrogen and R.sub.19 is --C(.dbd.O)-pyridyl, or R.sub.19 is hydrogen and R.sub.18 is --C(.dbd.O)-pyridyl, then when X is --NR.sub.2 --, R.sub.2 is not lower alkyl unless Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, nitro, or amino, and when X is --O--, --S--, or --NH--, then Y is not hydrogen, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, nitro, or amino;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

aryl is phenyl or ##STR163## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy;

and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group, in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group;

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

52. The compound of claim 51, wherein X is --N(R.sub.2)--.

53. The compound of claim 52, wherein R.sub.2 is (C.sub.1 -C.sub.18)alkanoyl or (C.sub.2 -C.sub.18)alkoxycarbonyl.

54. The compound of claim 51, wherein R.sub.18 is hydrogen and R.sub.19 is --(C.dbd.O)pyridyl.

55. The compound of claim 51, wherein R.sub.18 is hydrogen and R.sub.19 is ##STR164##

56. The compound of claim 55, which is N-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]-3-phenyl-2-quinoxa linamine, or its pharmaceutically acceptable acid addition salts.

57. An antipsychotic composition, which comprises the compound of claim 51 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

58. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 51.

59. An analgesic composition, which comprises the compound of claim 51 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.

60. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 51.

61. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 51, wherein the compound contains an acylated hydroxy group, or an acylated amino group.

62. The depot pharmaceutical composition of claim 61, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group.

63. The composition of claim 61, which contains a pharmaceutically acceptable oil.

64. The composition of claim 63, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

65. The composition of claim 62, which contains a pharmaceutically acceptable oil.

66. The composition of claim 65, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.

67. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 61 sufficient to produce a long acting antipsychotic effect.

68. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 62 sufficient to produce a long acting antipsychotic effect.

69. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 66 sufficient to produce a long acting antipsychotic effect.

70. An antipsychotic composition, which comprises a compound of the formula wherein,

X is --O--, --S--, ##STR165## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups, wherein aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy or halogen when p is 2 and X is --O--; in which (R.sub.1) is R.sub.20, R.sub.21 or R.sub.22, wherein:

R.sub.20 is --(CH.sub.2).sub.n --, where n is 2, 3, 4 or 5;

R.sub.21 is

--CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --,

--CH.sub.2 --CH.dbd.-CH--CH.sub.2 --CH.sub.2 --,

--CH.sub.2 --CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --CH.sub.2 --, or

--CH.sub.2 --CH.sub.2 --C.tbd.C--CH.sub.2 --,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1 -C.sub.6 linear alkyl group, phenyl group or ##STR166## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.12 straight or branched chain)alkyl, ##STR167## and where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl and piperazinyl;

in which aryl is phenyl or ##STR168## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

with the proviso that when R.sub.18 is alkyl and R.sub.19 is --C(.dbd.O)(C.sub.1 -C.sub.12)alkyl, or when R.sub.19 is alkyl and R.sub.18 is --C(.dbd.O)--(C.sub.1 -C.sub.12)alkyl, X is not S when Y is hydrogen and (R.sub.1) is R.sub.20 ;

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof;

in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.

71. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula ##STR169## wherein, X is --O--, --S--, ##STR170## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups, wherein aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is --O--; in which (R.sub.1) is R.sub.20, R.sub.21 or R.sub.22, wherein:

R.sub.20 is --(CH.sub.2).sub.n --, where n is 2, 3, 4 or 5;

R.sub.21 is

--CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --,

--CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2 --,

--CH.sub.2 --CH.sub.2 --CH.dbd.CH--CH.sub.2 --,

--CH.sub.2 --C.tbd.C--CH.sub.2 --CH.sub.2 --, or

--CH.sub.2 --CH.sub.2 --C.tbd.C--CH.sub.2 --,

the --CH.dbd.CH-- bond being cis or trans;

R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1 -C.sub.6 linear alkyl group, phenyl group or ##STR171## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen;

where R.sub.18 and R.sub.19 are independently selected from the group consisting of:

hydrogen,

(C.sub.1 -C.sub.12 straight or branched chain)alkyl, ##STR172## alkyl, ##STR173## alkyl; and where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl;

in which aryl is phenyl or ##STR174## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

with the proviso that R.sub.18 and R.sub.19 are not lower alkyl when X is --NR.sub.2 --, R.sub.2 is aryl, and Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, or lower alkoxy;

with the proviso that if either one of R.sub.18 and R.sub.19 is hydrogen or alkyl, then X is not S when Y is hydrogen, and (R.sub.1) is R.sub.20 or R.sub.21 ;

with the proviso that when R.sub.18 is alkyl and R.sub.19 is --C(.dbd.O)--(C.sub.1 -C.sub.12)alkyl, or when R.sub.19 is alkyl and R.sub.18 is --C(.dbd.O)--(C.sub.1 -C.sub.12)alkyl, X is not S when Y is hydrogen and (R.sub.1) is R.sub.20 ;

with the proviso that when R.sub.18 and R.sub.19 are both hydrogen, (R.sub.1) is not R.sub.20 or R.sub.21 when X is O or S;

and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group; in addition, any nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group; and

all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

72. The depot pharmaceutical composition of claim 71, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group.

73. The composition of claim 71, which contains a pharmaceutically acceptable oil.

74. The composition of claim 73, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and synthetic esters of fatty acids and polyfunctional alcohols.

75. The composition of claim 71, which contains a pharmaceutically acceptable oil.

76. The composition of claim 75, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and synthetic esters of fatty acids and polyfunctional alcohols.

77. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 71 sufficient to produce a long acting antipsychotic effect.

78. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 72 sufficient to produce a long acting antipsychotic effect.

79. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 76 sufficient to produce a long acting antipsychotic effect.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc